MariMed's Betty's Eddies Expands Top-Selling Brand With Introduction of THC & CBG-Infused Caramel Chews
Each Betty's Caramelt Away Chew Uses Rich, Buttery Caramel, To Create Moments of Mellow
NORWOOD, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- ™, the all-natural cannabis chews handcrafted to fit a variety of needs, is expanding its lineup with the introduction of delicious caramel chews: Betty's Caramelt Away. Betty's Eddies is one of the top-selling and award-winning brands developed and distributed by leading multi-state cannabis operator, MariMed Inc. ('MariMed') (CSE: MRMD) (OTCQX: MRMD).
Debuting in time for National Caramel Day on April 5, Betty's Caramelt Away chews are now available at select cannabis retailers throughout Massachusetts, with plans for expansion into MariMed's wholesale markets in the future. Each chew wraps customers in warmth with the rich, comforting flavor of classic caramel. They're infused with a soothing blend of full-spectrum hash and CBG that lets consumers sink into sweet, cozy melty moments of mellow.
'Betty's Eddies and caramel is the perfect pairing of two fan favorites,' said Sara Rosenfield, Brand Director at MariMed for Betty's Eddies. Betty's Eddies is the most popular edible brand in several of our core markets: Massachusetts, Maryland, and Delaware. Caramel consistently ranks among the most popular ingredients in candy and other sweet treats. Cannabis consumers will love the full-flavor, full-spectrum experience that the brand is known for with the creamy deliciousness of caramel.'
Betty's Caramelt Away joins a full slate of Betty's Eddies products that feature specific end-effects, including Bedtime Betty's for restful nights, Take It Easy Eddies for stress relief, Go Betty Go for an energy boost, Ache Away Eddies for pain relief, Smashin' Passion for sexual wellness, and Betty Good Times for any time.
About Betty's EddiesBetty's Eddies™ all-natural fruit chews are handcrafted with full-spectrum cannabis, supporting cannabinoids, and herbal supplements and vitamins. Designed for whatever life throws at you, varieties include pain relief, immunity, energy, sleep and more. Founded in 2014 by medical cannabis patients on a mission to craft the best tasting and most effective edibles, best-selling Betty's Eddies encompass the full spectrum of the plant's benefits, including natural adaptogens, and are handcrafted in small batches with real organic fruits and vegetables. Find Betty's Eddies in licensed dispensaries in Delaware, Maryland, Massachusetts, and Missouri. Learn more at www.bettyseddies.com.
About MariMedMariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty's Eddies™, Bubby's Baked™, Vibations™, InHouse™, and Nature's Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.
Media Contact:Zach GalassoDPA Communications Email: zach@dpacommunications.comPhone: (978) 604-5423
Company Contact:Howard SchacterChief Communications Officer Email: hschacter@marimedinc.comPhone: (781) 277-0007
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Remote Patient Monitoring Market Set to Reach USD 91.95 Billion by 2032, Driven by Rising Chronic Conditions and Technological Advancements
SNS Insider Unveils Strategic Insights into the U.S. Remote Patient Monitoring Market's Steady Expansion—Worth USD 12.76 Billion in 2024—While the North America Commands a 41.2% Share of Global Adoption Through Advanced Digital Health Ecosystem. Austin, June 11, 2025 (GLOBE NEWSWIRE) -- Remote Patient Monitoring Market Size & Growth Analysis: According to SNS Insider, The Remote Patient Monitoring market was estimated at USD 35.47 billion in 2024 and is expected to reach USD 91.95 billion by 2032, at a CAGR of 12.69% during the forecast period of 2024-2032. The market is experiencing rapid expansion, driven by increasing demand for real-time health monitoring systems, particularly among patients managing chronic conditions such as cardiovascular disease and diabetes. Technological advancements in wearable devices, along with the integration of AI-based algorithms, are enhancing the accuracy, reliability, and efficiency of remote monitoring a Sample Report of Remote Patient Monitoring Market@ The U.S. RPM market alone was valued at USD 12.76 billion in 2024 and is expected to grow to USD 32.17 billion by 2032, with a projected CAGR of 12.30% during the forecast period. The United States dominates the North American RPM market, supported by a robust healthcare infrastructure, favorable reimbursement policies, and widespread adoption of digital health technologies. RPM usage is accelerating due to federal efforts to reduce dependency on in-person visits and the rising prevalence of chronic conditions. As a result, the U.S. is expected to remain a major growth driver within the region. Major Players Analysis Listed in this Report are: Philips Healthcare Medtronic GE HealthCare Honeywell Life Sciences Abbott Laboratories Boston Scientific Biotronik Omron Healthcare Dexcom ResMed iRhythm Technologies VitalConnect BioTelemetry (a Philips company) Masimo Corporation Welch Allyn (Hill-Rom) Remote Patient Monitoring Market Report Scope Report Attributes Details Market Size in 2024 US$ 35.47 billion Market Size by 2032 US$ 91.95 billion CAGR CAGR of 12.69% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Insights Market by Component, Devices & Software Segment Held the largest Market Portion In the year 2024, the devices & software segment dominated the market with a 56.1% market share, owing to its vital role in the provision of real-time collection, transmission, and analysis of health data. With the emergence of chronic conditions, particularly cardiovascular diseases and diabetes, wearable devices, biosensors, and connected monitoring tools play a huge role in patient care. User-friendly interfaces, mobile integration, and cloud-based platforms have also enhanced the efficiency and scalability of RPM solutions. The Segment of Cardiovascular Diseases Leads the Market by Application In 2024, the remote patient monitoring market was dominated by the cardiovascular diseases segment, due to heart-related diseases are the leading global cause of death, and the constant need for monitoring is essential to proper management of these diseases. RPM solutions use ECG monitors, Blood pressure cuffs, and heart rate trackers to collect real-time data and spot any complications early, reducing hospital admissions By End-User, the Hospitals Segment Dominates the Market In 2024, the hospitals segment accounted for the largest share of the Remote Patient Monitoring market with a 47.5% market share, owing to their higher consideration factor to include Remote Patient Monitoring technologies, and their robust infrastructure and clinical expertise. Hospitals are leading the way in using RPM to manage chronic disease, support post-discharge care, and improve outcomes. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Remote Patient Monitoring Market Segmentation By Component Services Devices & Software By Application Cardiovascular Diseases Respiratory Diseases Diabetes Musculoskeletal Diseases Others By End-User Hospitals Home Healthcare Settings Ambulatory Care Settings Long-Term Care Centers North America Dominated the Market, Asia Pacific Expected to Exhibit the Fastest Growth North America led the global RPM market in 2024, holding a 41.2% market share. This leadership is supported by a mature healthcare system, supportive government policies, and high acceptance of digital health technologies. The presence of major RPM solution providers and a growing elderly population with chronic illnesses further fuels market demand. Meanwhile, the Asia-Pacific region is projected to witness the fastest growth during the forecast period. This growth is driven by increased healthcare digitization, improving internet and telecommunications infrastructure, and rising awareness of remote healthcare services. Countries such as China, Japan, and India are investing heavily in telemedicine to bridge rural healthcare gaps. The surge in chronic diseases and growing popularity of in-home and mobile health platforms are also key contributors to regional market expansion. Buy a Single-User PDF of Remote Patient Monitoring Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Chronic Disease Burden & Aging Population (2024) 5.2 Remote Patient Monitoring Adoption Trends by Region (2024) 5.3 Reimbursement Coverage & Healthcare Spending Trends (2024) 5.4 Hospital Readmission Reduction and Cost-Saving Impact (2024) 6. Competitive Landscape 7. Remote Patient Monitoring Market by Component 8. Remote Patient Monitoring Market by Application 9. Remote Patient Monitoring Market by End-User 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
The Joint Commission and Coalition for Health AI Join Forces to Scale the Responsible Use of AI in Delivering Better Healthcare
Partners to Drive Private Sector-based Development and Adoption of AI Best Practices and Guidance in Over 80 Percent of Healthcare Organizations and Programs in the U.S. OAKBROOK TERRACE, Illinois, June 11, 2025 (GLOBE NEWSWIRE) -- The Joint Commission, an independent, evidence-based healthcare standard setting organization, and the Coalition for Health AI (CHAI), a nonprofit organization founded by clinicians to advance responsible health AI, announced today a new partnership to accelerate the development and adoption of AI best practices and guidance across the U.S. healthcare system. Together, the organizations will use their scale and expertise to co-develop a suite of AI playbooks, tools, and a new certification program rooted in The Joint Commission's platform for evidence-based standards, and CHAI's consensus-based best practices for health AI. 'In the decade ahead, nothing has the capacity to change healthcare more than AI in terms of innovation, transformation and disruption,' said Jonathan B. Perlin, MD, PhD, president and CEO of The Joint Commission. 'While it's impossible to predict exactly what healthcare will look like over that time, AI's integration and potential to improve quality patient care is enormous – but only if we do it right. By working with CHAI, we are creating a roadmap and offering guidance for healthcare organizations so they can harness this technology in ways that not only support safety but engender trust among stakeholders.' Adoption of AI in healthcare, from patient monitoring to drug approvals, is rapidly increasing. According to 2024 research, 46% of US healthcare organizations are in initial implementation of generative AI, and that number is only expected to grow. While the industry is embracing uses for AI, guidance on implementation is needed for all organizations to protect their staff, patients and operations. To meet this demand, this partnership will be the first to issue AI guidance for over 80 percent of healthcare organizations and programs in the U.S. 'Partnering with The Joint Commission means we can help healthcare organizations utilize AI and the many benefits these new technologies bring, at a scale we have never been able to achieve before,' said Dr. Brian Anderson, MD, President and CEO of CHAI. 'Together, we're leading the transformation of data-driven healthcare, one where AI is embedded into every healthcare program – regardless of population, geographic area, or resources – to elevate patient safety and quality, and ultimately improve health outcomes for all.' By bringing together CHAI's broad-based membership and expertise in safe AI, and the reach of The Joint Commission-accredited hospitals and health systems, the two organizations are setting the standards for AI adoption in healthcare. Started by clinicians, CHAI was founded to build the broadest possible consensus across the health ecosystem to help ensure health AI is trusted and safe. Its membership has grown to 3,000 organizations, including academic medical centers, regional and rural health systems, healthcare technology leaders and start-ups, government experts and patient advocates. 'The integration of AI into healthcare presents both significant opportunities and complex challenges. This effort between The Joint Commission and the Coalition for Health AI represents a thoughtful approach to navigating how to best deploy and implement these emerging technologies,' said Michael Pfeffer, M.D., Chief Information and Digital Officer, Stanford Health Care. 'This partnership, the guidance, tools and certification it aims to provide will help accelerate innovation, mitigate risk, and enable healthcare organizations to fully leverage AI's potential to improve patient outcomes and clinician workflows.' The first guidance will be available in Fall 2025. AI certification will follow. About The Joint Commission Founded in 1951, The Joint Commission seeks to continuously improve healthcare for the public, in collaboration with other stakeholders, by evaluating healthcare organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. The Joint Commission accredits and certifies more than 23,000 healthcare organizations and programs in the United States. An independent, nonprofit organization, The Joint Commission is the nation's oldest and largest standards-setting and accrediting body in healthcare. Learn more about The Joint Commission at About Coalition for Health AI (CHAI) The CHAI (Coalition for Health AI) mission is to be the trusted source of guidelines for responsible AI in health that serves all. It aims to ensure high-quality care, foster trust among users, and meet the growing healthcare needs. CHAI membership is open and rapidly expanding with 3,000 organizations including health systems, patient advocacy groups, and a wide range of industry leaders and start-ups across the healthcare and technology ecosystems. CHAI is committed to convening and dialogue to achieve consensus. There is no limit to who can join and participate. Learn more about a CHAI membership here. CONTACT: Katie Bronk The Joint Commission 630-792-5175 kbronk@ Andrea Heuer Coalition for Health AI 917-914-5563 CHAI@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ('Conavi Medical' or the 'Company'), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025 DATE: June 12th TIME: 2:00 PM ETLINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition U.S. FDA 510(k) submission remains on track for calendar Q3 2025 About Conavi MedicalConavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Forward-Looking StatementsThis press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi's exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking information or statements". Often but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "anticipate", "believe", "plan", "expect", "intend", "estimate" "anticipate" or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the "Risk Factors" section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or regulatory authority has approved or disapproved the content of this press the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts: Conavi MedicalStefano PiconeChief Financial Officerir@ 483-0100 Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
